PEGFILGRASTIM-CBQV: 732 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
732
Total FAERS Reports
104 (14.2%)
Deaths Reported
94
Hospitalizations
732
As Primary/Secondary Suspect
3
Life-Threatening
2
Disabilities
Prescription
Status
FDA Application: 761039 ·
First Report: 20160101 · Latest Report: 20250826
What Are the Most Common PEGFILGRASTIM-CBQV Side Effects?
#1 Most Reported
Device malfunction
356 reports (48.6%)
#2 Most Reported
No adverse event
265 reports (36.2%)
#3 Most Reported
Death
76 reports (10.4%)
All PEGFILGRASTIM-CBQV Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Device malfunction | 356 | 48.6% | 1 | 3 |
| No adverse event | 265 | 36.2% | 0 | 0 |
| Death | 76 | 10.4% | 76 | 4 |
| Product dose omission issue | 61 | 8.3% | 3 | 5 |
| Product label confusion | 36 | 4.9% | 0 | 1 |
| Accidental exposure to product | 29 | 4.0% | 0 | 0 |
| Neutrophil count decreased | 18 | 2.5% | 0 | 9 |
| Bone pain | 17 | 2.3% | 0 | 2 |
| Device failure | 16 | 2.2% | 0 | 1 |
| Product packaging confusion | 16 | 2.2% | 0 | 0 |
| Product quality issue | 15 | 2.1% | 0 | 1 |
| Hospitalisation | 14 | 1.9% | 1 | 13 |
| Device leakage | 13 | 1.8% | 0 | 0 |
| Febrile neutropenia | 13 | 1.8% | 0 | 12 |
| Drug ineffective | 12 | 1.6% | 0 | 6 |
| Syringe issue | 12 | 1.6% | 0 | 0 |
| Back pain | 11 | 1.5% | 3 | 6 |
| Dyspnoea | 11 | 1.5% | 0 | 6 |
| Nausea | 11 | 1.5% | 3 | 5 |
| Neutropenia | 11 | 1.5% | 1 | 3 |
Who Reports PEGFILGRASTIM-CBQV Side Effects? Age & Gender Data
Gender: 60.3% female, 39.7% male. Average age: 55.2 years. Most reports from: US. View detailed demographics →
Is PEGFILGRASTIM-CBQV Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 1 | 0 | 0 |
| 2018 | 1 | 0 | 0 |
| 2019 | 56 | 5 | 25 |
| 2020 | 62 | 14 | 18 |
| 2021 | 31 | 15 | 7 |
| 2022 | 17 | 6 | 2 |
| 2023 | 8 | 4 | 0 |
| 2024 | 248 | 12 | 13 |
| 2025 | 140 | 3 | 2 |
What Is PEGFILGRASTIM-CBQV Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 409 |
| Infection prophylaxis | 62 |
| Prophylaxis | 57 |
| Neutropenia | 19 |
| Pancreatic carcinoma | 12 |
| Agranulocytosis | 8 |
| Breast cancer | 8 |
| Chemotherapy | 8 |
| Febrile neutropenia | 8 |
| Breast cancer female | 6 |
PEGFILGRASTIM-CBQV vs Alternatives: Which Is Safer?
PEGFILGRASTIM-CBQV vs PEGFILGRASTIM-JMDB
PEGFILGRASTIM-CBQV vs PEGINTERFERON ALFA
PEGFILGRASTIM-CBQV vs PEGINTERFERON ALFA-2A
PEGFILGRASTIM-CBQV vs PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B
PEGFILGRASTIM-CBQV vs PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B OR PEGINTERFERON BETA-1A OR PEGINTERFERON LAMBDA-1A
PEGFILGRASTIM-CBQV vs PEGINTERFERON ALFA-2B
PEGFILGRASTIM-CBQV vs PEGINTERFERON BETA-1A
PEGFILGRASTIM-CBQV vs PEGINTRON
PEGFILGRASTIM-CBQV vs PEGLOTICASE
PEGFILGRASTIM-CBQV vs PEGUNIGALSIDASE ALFA-IWXJ
Official FDA Label for PEGFILGRASTIM-CBQV
Official prescribing information from the FDA-approved drug label.